This Article Full Text Full Text (PDF) All Versions of this Article: 40/5/1877    most recent STROKEAHA.108.540765v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wang, X. Articles by Friedlander, R. M. Search for Related Content PubMed PubMed Citation Articles by Wang, X. Articles by Friedlander, R. M. Related Collections Animal models of human disease Apoptosis Neuroprotectors

(Stroke. 2009;40:1877.)
© 2009 American Heart Association, Inc.

Original Contributions

Methazolamide and Melatonin Inhibit Mitochondrial Cytochrome C Release and Are Neuroprotective in Experimental Models of Ischemic Injury

Xin Wang, PhD; Bryan E. Figueroa, MD; Irina G. Stavrovskaya, PhD; Yi Zhang, PhD; Ana C. Sirianni, MS; Shan Zhu, PhD; Arthur L. Day, MD; Bruce S. Kristal, PhD Robert M. Friedlander, MD, MA

From the Neuroapoptosis Laboratory (X.W., B.E.F., Y.Z., A.C.S., S.Z., R.M.F.), Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass; Department of Neurosurgery (I.G.S., A.L.D., B.S.K.), Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass.

Correspondence to Robert M. Friedlander, MD, MA, Brigham and Women’s Hospital, Harvard Medical School, LMRC 111-113, Department of Neurosurgery, Boston, MA 02115. E-mail rfriedlander{at}rics.bwh.harvard.edu

Background and Purpose— The identification of a neuroprotective drug for stroke remains elusive. Given that mitochondria play a key role both in maintaining cellular energetic homeostasis and in triggering the activation of cell death pathways, we evaluated the efficacy of newly identified inhibitors of cytochrome c release in hypoxia/ischemia induced cell death. We demonstrate that methazolamide and melatonin are protective in cellular and in vivo models of neuronal hypoxia.

Methods— The effects of methazolamide and melatonin were tested in oxygen/glucose deprivation–induced death of primary cerebrocortical neurons. Mitochondrial membrane potential, release of apoptogenic mitochondrial factors, pro–IL-1β processing, and activation of caspase -1 and -3 were evaluated. Methazolamide and melatonin were also studied in a middle cerebral artery occlusion mouse model. Infarct volume, neurological function, and biochemical events were examined in the absence or presence of the 2 drugs.

Results— Methazolamide and melatonin inhibit oxygen/glucose deprivation–induced cell death, loss of mitochondrial membrane potential, release of mitochondrial factors, pro–IL-1β processing, and activation of caspase-1 and -3 in primary cerebrocortical neurons. Furthermore, they decrease infarct size and improve neurological scores after middle cerebral artery occlusion in mice.

Conclusions— We demonstrate that methazolamide and melatonin are neuroprotective against cerebral ischemia and provide evidence of the effectiveness of a mitochondrial-based drug screen in identifying neuroprotective drugs. Given the proven human safety of melatonin and methazolamide, and their ability to cross the blood-brain-barrier, these drugs are attractive as potential novel therapies for ischemic injury.

Key Words: methazolamide • melatonin • neuroprotection • ischemic stroke